基于mpMRI临床分期的MSKCC与Briganti列线图预测前列腺癌淋巴结受累的外部验证
本研究回顾性纳入2015-2019年三家教学医院行机器人辅助扩大盆腔淋巴结清扫的1062例前列腺癌患者,评估mpMRI与DRE评估的T分期对MSKCC 2018和Briganti 2012列线图预测淋巴结受累性能的影响。结果显示mpMRI T分期是DRE的合适替代,且Briganti 2012联合mpMRI T分期在AUC、校准和净获益上更优。
要点
- mpMRI T分期可替代DRE T分期用于列线图预测淋巴结受累风险。
- Briganti 2012联合mpMRI T分期在AUC、校准和净获益上表现更优。
- 使用mpMRI T分期提高所有风险阈值的敏感性,但降低特异性。
核心结论
- mpMRI评估的T分期是DRE评估T分期的合适替代,用于确定基于列线图的前列腺癌患者淋巴结受累风险,并与MSKCC 2018和Briganti 2012列线图模型性能改善相关。
研究设计与样本
- 回顾性评估2015至2019年在三家教学医院接受机器人辅助扩大盆腔淋巴结清扫的患者。
- 共纳入1062例患者,其中301例(28%)经组织学证实存在淋巴结受累。
- 对每例患者使用DRE和mpMRI评估的临床T分期,分别代入MSKCC(2018)和Briganti(2012)列线图计算淋巴结受累风险,共四次。
- 评估并比较四种策略的区分度(AUC)、校准和净获益。
主要发现
- 使用DRE T分期时,MSKCC列线图AUC为0.71(95%CI 0.70-0.72),Briganti列线图AUC为0.73(95%CI 0.72-0.74)。
- 使用mpMRI T分期时,MSKCC列线图AUC为0.72(95%CI 0.71-0.73),Briganti列线图AUC为0.75(95%CI 0.74-0.76)。
- mpMRI T分期与DRE T分期相比校准等效。
- 联合使用mpMRI T分期和Briganti 2012列线图在AUC、校准和净获益方面更优。
- 与DRE T分期相比,使用mpMRI T分期提高两个模型在所有风险阈值下检测淋巴结受累的敏感性,但特异性降低。
临床怎么用
- 在前列腺癌患者中,可使用mpMRI评估的T分期替代DRE T分期代入MSKCC 2018或Briganti 2012列线图计算淋巴结受累风险。
- 联合mpMRI T分期与Briganti 2012列线图可能改善风险预测的区分度、校准和净获益。
- 需注意mpMRI T分期提高敏感性但降低特异性,临床决策时应结合患者具体情况。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the impact of using clinical stage assessed by multiparametric magnetic resonance imaging (mpMRI) on the performance of two established nomograms for the prediction of pelvic lymph node involvement (LNI) in patients with prostate cancer. PATIENTS AND METHODS: Patients undergoing robot-assisted extended pelvic lymph node dissection (ePLND) from 2015 to 2019 at three teaching hospitals were retrospectively evaluated. Risk of LNI was calculated four times for each patient, using clinical tumour stage (T-stage) assessed by digital rectal examination (DRE) and by mpMRI, in the Memorial Sloan Kettering Cancer Centre (MSKCC; 2018) and Briganti (2012) nomograms. Discrimination (area under the curve [AUC]), calibration, and the net benefit of these four strategies were assessed and compared. RESULTS: A total of 1062 patients were included, of whom 301 (28%) had histologically proven LNI. Using DRE T-stage resulted in AUCs of 0.71 (95% confidence interval [CI] 0.70-0.72) for the MSKCC and 0.73 (95% CI 0.72-0.74) for the Briganti nomogram. Using mpMRI T-stage, the AUCs were 0.72 (95% CI 0.71-0.73) for the MSKCC and 0.75 (95% CI 0.74-0.76) for the Briganti nomogram. mpMRI T-stage resulted in equivalent calibration compared with DRE T-stage. Combined use of mpMRI T-stage and the Briganti 2012 nomogram was shown to be superior in terms of AUC, calibration, and net benefit. Use of mpMRI T-stage led to increased sensitivity for the detection of LNI for all risk thresholds in both models, countered by a decreased specificity, compared with DRE T-stage. CONCLUSION: T-stage as assessed by mpMRI is an appropriate alternative for T-stage assessed by DRE to determine nomogram-based risk of LNI in patients with prostate cancer, and was associated with improved model performance of both the MSKCC 2018 and Briganti 2012 nomograms.
引用
- Soeterik TFW, Hueting TA, Israel B, et al. External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging. BJU Int. 2021. PMID: 33630398. doi:10.1111/bju.15376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。